Just in time for Rare Disease Day. 🔥 Honored to chair the TargetCancer national Molecular Tumor Board 🧬🧬and TRACK trial. Experts from MCW, MDACC, Dana Farber/Harvard, Hopkins, UCSD, FMI and more all coming together to help cancer pts across the USA. 🇺🇸🚀🎯🧬🧬

Missing the buzz 🐝 of GU ASCO #GU25? Dana-Farber Lank Center for Genitourinary Oncology has got you covered! Join Toni Choueiri, MD Bradley McGregor Atish Choudhury, MD PhD as we discuss what we learned and where we’re going next! Prostate 🔗 youtu.be/F4HO10wkkdg Bladder 🔗 youtu.be/1cspRGBjMZI Kidney 🔗

Learn about the advances our colleagues from Dana-Farber Lank Center for Genitourinary Oncology have made recently! Dana-Farber Dana-Farber News Atish Choudhury, MD PhD Misha Beltran Alicia Morgans, MD, MPH Stephanie Berg Michael Serzan, MD Eli Van Allen KaelinLab Wenxin (Vincent) Xu Praful Ravi et al

Thank you AACR ! cc: Dana-Farber Lank Center for Genitourinary Oncology #WCRM

Our own Dana-Farber Dr. Narjust Florez, MD, FASCO is running for IASLC Board. Let us support NJ! Dana-Farber News

📢 #ASCO25 | KEYNOTE-564 Ph. III | 5-Year Update (LBA–TBC): Adjuvant pembrolizumab vs placebo in high risk pts with ccRCC continues to show durable benefit—DFS HR 0.71 (DFS rate at 5 yrs 68.3% vs 52.2%) & OS HR 0.66 (OS rate at 5 yrs 87.7% vs 82.3%). No new safety signals.

Congrats Tian Zhang, MD, MHS and Toni Choueiri, MD Alliance for Clinical Trials in Oncology for A031704/PDIGREE step 1 results and the years it took, persistence and trial design with patient support ! Largest RCC trial in the NCTN to date!

📢 #ASCO25 | CM 9ER Biomarker Analysis | 651 pts aRCC: Integrative analysis of circulating (e.g., early ctDNA clearance, peripheral immune subsets) & TME (CD8+ TIL density, PD‑L1 expression) determinants of response to NIVO+CABO. High baseline CD8+ TILs & ctDNA clearance

Fantastic presentation by Renee Maria Saliby discussing our work evaluating MAdCAM-1, a circulating surrogate of gut dysbiosis, as a biomarker in patients with mRCC! #ASCO25 ASCO Toni Choueiri, MD Carolina Alves Costa Silva, MD, PhD OncoAlert

Who will be the heme/onc fellowship that is lucky to get Renee Maria Saliby ???? #ASCO25 ASCO

Incredible and insightful discussion of kidney cancer biomarkers at #ASCO25. Increasingly there are biomarkers being validated across multiple randomized studies. Dr. David McDermott makes a poignant and urgent case for prospectively validating these in prospective trials.

#ASCO25 Final results of IO-based combinations in mRCC are in! See below and subsequent posts for thoughts. Video discussing these data coming soon from OncoAlert...

.Toni Choueiri, MD discusses promising results from the phase 1 ARC-20 study, exploring the combination of Casdatifan and cabozantinib in patients with previously treated clear cell renal cell carcinoma. #ASCO25

📢 #ASCO25 | Docetaxel + ADT + RT | High-Risk Localized Prostate CA: ICECaP IPD Meta-analysis (n=1,690) of RT + ADT ± docetaxel shows no significant MFS benefit overall (HR 0.89, p=0.16) or OS (HR 0.88, p=0.17), with a trend in very high-risk pts (MFS HR 0.86). Great talk by our

The whole team at the Gelb Center for Translational Research Dana-Farber Lank Center for Genitourinary Oncology are so proud of Ilana's poster presentation and many other achievements!

Congratulations Toni Choueiri, MD! So well-deserved and a true testament to your huge impact on our field 👏👏

Unparalleled opportunity for a head/neck oncologist Dana-Farber under Robert Haddad leadership ! NEJM ASCO Journal of Clinical Oncology OncoAlert IMG Oncologists

As the waves 🌊 settle after #ASCO25 we Dana-Farber Lank Center for Genitourinary Oncology take a deeper dive 🤿 into the most impactful data! Join Toni Choueiri, MD Bradley McGregor Atish Choudhury, MD PhD as we discuss what we learned & where we’re going next! Prostate 🔗 youtu.be/heLQLuWjlzM Bladder 🔗

If you would like a free recap of what happened at #ASCO2025 in term of #GU Oncology, feel free to tune in to our Dana-Farber Lank Center for Genitourinary Oncology highlights: presentations of top abstracts + discussion. Initiative led by Michael Serzan, MD Dana-Farber

Grants and awards ⁦KidneyCAN⁩ #KCRS2025. Congratulations ⁦Rana McKay, MD, FASCO⁩ ⁦UC San Diego Health Moores Cancer Center⁩ and ⁦Srinivas Viswanathan⁩ ⁦Dana-Farber⁩